Family Management Corp Has $694,000 Holdings in Merck & Co., Inc. (NYSE:MRK)

Share on StockTwits

Family Management Corp cut its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 76.2% in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,281 shares of the company’s stock after selling 26,479 shares during the period. Family Management Corp’s holdings in Merck & Co., Inc. were worth $694,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Titan Capital Management LLC CA acquired a new stake in shares of Merck & Co., Inc. during the second quarter worth $25,000. LFA Lugano Financial Advisors SA lifted its holdings in Merck & Co., Inc. by 250.0% during the second quarter. LFA Lugano Financial Advisors SA now owns 315 shares of the company’s stock worth $26,000 after acquiring an additional 225 shares in the last quarter. JJJ Advisors Inc. bought a new position in Merck & Co., Inc. during the second quarter worth about $27,000. Cumberland Partners Ltd bought a new position in Merck & Co., Inc. during the second quarter worth about $40,000. Finally, Fusion Family Wealth LLC lifted its holdings in Merck & Co., Inc. by 268.2% during the second quarter. Fusion Family Wealth LLC now owns 486 shares of the company’s stock worth $41,000 after acquiring an additional 354 shares in the last quarter. 74.97% of the stock is owned by institutional investors and hedge funds.

In other news, EVP Richard R. Deluca sold 6,427 shares of the company’s stock in a transaction that occurred on Friday, August 9th. The stock was sold at an average price of $85.09, for a total value of $546,873.43. Following the transaction, the executive vice president now owns 103,223 shares of the company’s stock, valued at $8,783,245.07. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Robert M. Davis sold 216,718 shares of the company’s stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $85.43, for a total value of $18,514,218.74. Following the completion of the transaction, the chief financial officer now directly owns 354,378 shares in the company, valued at approximately $30,274,512.54. The disclosure for this sale can be found here. 0.27% of the stock is owned by insiders.

NYSE MRK traded up $1.38 during trading on Friday, reaching $85.35. 4,529,693 shares of the company’s stock were exchanged, compared to its average volume of 7,392,823. The business has a 50 day moving average price of $84.89 and a 200-day moving average price of $81.95. The stock has a market capitalization of $211.26 billion, a P/E ratio of 19.66, a PEG ratio of 1.68 and a beta of 0.53. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.21 and a quick ratio of 0.92. Merck & Co., Inc. has a fifty-two week low of $66.10 and a fifty-two week high of $87.35.

Merck & Co., Inc. (NYSE:MRK) last announced its quarterly earnings results on Tuesday, July 30th. The company reported $1.30 earnings per share for the quarter, topping analysts’ consensus estimates of $1.16 by $0.14. The firm had revenue of $11.76 billion for the quarter, compared to the consensus estimate of $10.94 billion. Merck & Co., Inc. had a return on equity of 43.34% and a net margin of 21.10%. The business’s revenue was up 12.4% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.06 earnings per share. On average, analysts forecast that Merck & Co., Inc. will post 4.91 earnings per share for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, October 7th. Shareholders of record on Monday, September 16th will be given a dividend of $0.55 per share. This represents a $2.20 dividend on an annualized basis and a yield of 2.58%. The ex-dividend date is Friday, September 13th. Merck & Co., Inc.’s dividend payout ratio (DPR) is presently 50.69%.

Several research firms have weighed in on MRK. Morgan Stanley lifted their target price on Merck & Co., Inc. from $84.00 to $90.00 and gave the stock an “overweight” rating in a report on Friday, June 21st. Citigroup lifted their target price on Merck & Co., Inc. from $84.00 to $95.00 and gave the stock a “buy” rating in a report on Friday, June 21st. They noted that the move was a valuation call. Mizuho reiterated a “buy” rating and set a $97.00 target price on shares of Merck & Co., Inc. in a report on Sunday, September 8th. Bank of America set a $97.00 target price on Merck & Co., Inc. and gave the stock a “buy” rating in a report on Thursday, July 11th. Finally, Credit Suisse Group reiterated a “buy” rating and set a $95.00 target price on shares of Merck & Co., Inc. in a report on Wednesday, August 7th. Three investment analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. The stock has a consensus rating of “Buy” and a consensus price target of $93.29.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Featured Article: Death Cross

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Rentokil Initial’s  “Hold” Rating Reaffirmed at Peel Hunt
Rentokil Initial’s “Hold” Rating Reaffirmed at Peel Hunt
Grafton Group  Downgraded by Peel Hunt to “Hold”
Grafton Group Downgraded by Peel Hunt to “Hold”
Deutsche Wohnen  Given a €35.20 Price Target at Goldman Sachs Group
Deutsche Wohnen Given a €35.20 Price Target at Goldman Sachs Group
DigitalNote  Market Capitalization Achieves $4.21 Million
DigitalNote Market Capitalization Achieves $4.21 Million
BlockMesh Market Capitalization Hits $112,267.00
BlockMesh Market Capitalization Hits $112,267.00
Nectar  Hits One Day Volume of $3,300.00
Nectar Hits One Day Volume of $3,300.00


© 2006-2019 Ticker Report